Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The 'herbal medicine combination' is a specific multi-ingredient phytotherapeutic supplement developed by researchers at the University of Melbourne, led by Dr. Diana van Die. It consists of four standardized botanical extracts: turmeric (Curcuma longa), resveratrol (Polygonum cuspidatum), green tea (Camellia sinensis), and broccoli sprouts (Brassica oleracea). This combination was evaluated in the PC-PRoC (Prostate Cancer-Phytotherapeutic Response and Control) trial, a double-blind, randomized pilot study involving men with biochemically recurrent prostate cancer and a moderate PSA rise rate. The primary objective of the combination is to slow the progression of prostate cancer by extending the PSA doubling time, potentially through the synergistic antioxidant, anti-inflammatory, and anti-proliferative effects of its constituents. The herbal materials for the study were provided by Integria Healthcare and MediHerb.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on herbal medicine combination.